$KZIA

Kazia Therapeutics (KZIA) announced that Sovargen Co. dosed the first patient in a Phase 1b/2a trial of paxalisib for rare seizure disorders. The milestone triggers a $2 million payment to Kazia, with potential for up to $17 million more. Paxalisib is being developed for intractable epilepsy associated with FCD T2 and TSC, with Kazia retaining oncology focus.

Kazia Therapeutics (NASDAQ: KZIA) announced the first patient has been dosed in a Phase 2 study (PNOC035) evaluating paxalisib plus gemcitabine for recurrent pediatric AT/RT brain cancer. The study, conducted by the Pediatric Neuro-Oncology Consortium, aims to address a condition with no approved therapies. Preclinical data showed a significant survival increase, supporting the trial's rationale. Paxalisib has received FDA orphan drug and rare pediatric disease designations for AT/RT.

Kazia Therapeutics (KZIA) raised $40M in a public offering, with potential for $120M including warrant exercises. The company is expanding a breast cancer study for paxalisib, targeting enrollment by 2027. Proceeds support clinical trials and working capital, but preclinical evidence is still early.

BTIG maintained a 'Buy' rating on Kazia Therapeutics (KZIA) and raised its price target to $40 from $34. The company has a market cap of $203.16M and a GF Score of 33, indicating concerns in financial health and profitability. Analysts are optimistic about its drug development efforts, particularly Paxalisib for brain cancer. The stock has a high P/S ratio of 127.89x, suggesting potential overvaluation.

Kazia Therapeutics (KZIA) reported paxalisib reduced tumor burden by 52% in a colorectal cancer model. The company plans a Phase 2 trial in 2027, evaluating paxalisib alone and with immunotherapy. Kazia is developing biomarkers and has filed a patent for colorectal cancer applications.

BTIG raised its price target for Kazia Therapeutics (NASDAQ:KZIA) to $40 from $34, citing positive trial data for paxalisib in metastatic triple-negative breast cancer. The stock has surged nearly 100% year-to-date to $12.71. Kazia also announced a $40 million public offering. BTIG noted the data showed an 83% overall response rate and no serious adverse events.

Kazia Therapeutics reported preclinical data showing its drug paxalisib reduced tumor burden in MSS/pMMR colorectal cancer by 52%. Combining it with pembrolizumab further reduced tumor volume by 50%. The company plans a Phase 2 trial in 2027, with safety and survival as key endpoints. Paxalisib is well-tolerated and has shown potential in overcoming immunotherapy resistance.

Kazia Therapeutics (NASDAQ: KZIA) is expanding its clinical trial for paxalisib to include HR+/HER2- breast cancer, following preclinical data showing strong antitumor activity and safety. The trial will evaluate paxalisib combined with standard therapies, with enrollment expected by 2027. The company filed a related patent and aims to present additional data later this year.

Kazia Therapeutics (NASDAQ: KZIA) closed an oversubscribed public offering, raising $40 million upfront. The offering includes milestone-linked warrants, potentially adding $80 million if exercised, totaling $120 million. Proceeds will fund clinical trials for paxalisib and general corporate purposes. The company will host a corporate update call on September 1, 2026.

Kazia Therapeutics (NASDAQ: KZIA) reported that its lead drug, paxalisib, achieved a 100% clinical benefit rate in six patients with advanced triple-negative breast cancer. Five patients showed a measurable reduction in tumors, with one complete response. No serious adverse events were observed. The company is enrolling patients in a Phase 1b trial, with interim updates expected in 2026 and 2027.